
Cognition Therapeutics Investor Relations Material
Latest events

Q4 2024
Cognition Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cognition Therapeutics Inc
Access all reports
Cognition Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing small molecule therapeutics aimed at treating age-related degenerative diseases and disorders affecting the central nervous system and retina. The company's research focuses on developing a portfolio of small molecule product candidates targeting the sigma-2 receptor (S2R) complex. This receptor complex is a crucial regulator of the cellular damage response for conditions such as Alzheimer's disease , dry age-related macular degeneration (dry AMD), geographic atrophy, among others. Cognition Therapeutics is headquartered in Purchase, New York, and its shares are listed on the Nasdaq.
Key slides for Cognition Therapeutics Inc


Study Update
Cognition Therapeutics Inc


Study Update
Cognition Therapeutics Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
CGTX
Country
🇺🇸 United States